Somatic mutations are frequently detected in CML patients before treatment-free remission (TFR) attempt with tyrosine kinase inhibitor (TKI) discontinuation but with uncertain predictive valu efor Tfr failure
PERUSINI, MA., K. PAGNANO, C. PAVLOVSKY, K. PAGNANO, B. MOIRAGHI et. al.
Somatic mutations are frequently detected in CML patients before treatment-free remission (TFR) attempt with tyrosine kinase inhibitor (TKI) discontinuation but with uncertain predictive valu efor Tfr failure
Autoři
PERUSINI, MA., K. PAGNANO, C. PAVLOVSKY, K. PAGNANO, B. MOIRAGHI, AI. VARELA, M. BIANCHINI, Jiří MAYER, Daniela ŽÁČKOVÁ, Anežka KVETKOVÁ, Tomáš JURČEK, Ivana JEŽÍŠKOVÁ, ABP. LOPES, G. DUARTE, CA. SOUZA, J. MEDEIROS, TS. KIM, YS. YOO, KH. KIM, HW. LEE, MH. CHANG, SY. YI, S. ABELSON a D. KIM
Vydání
64th ASH Annual Meeting and Exposition, USA, New Orleans, prosinec 2022 in Blood, 2022
PERUSINI, MA., K. PAGNANO, C. PAVLOVSKY, K. PAGNANO, B. MOIRAGHI, AI. VARELA, M. BIANCHINI, Jiří MAYER, Daniela ŽÁČKOVÁ, Anežka KVETKOVÁ, Tomáš JURČEK, Ivana JEŽÍŠKOVÁ, ABP. LOPES, G. DUARTE, CA. SOUZA, J. MEDEIROS, TS. KIM, YS. YOO, KH. KIM, HW. LEE, MH. CHANG, SY. YI, S. ABELSON a D. KIM. Somatic mutations are frequently detected in CML patients before treatment-free remission (TFR) attempt with tyrosine kinase inhibitor (TKI) discontinuation but with uncertain predictive valu efor Tfr failure. In 64th ASH Annual Meeting and Exposition, USA, New Orleans, prosinec 2022 in Blood. 2022.
@proceedings{2241222, author = {Perusini, MA. and Pagnano, K. and Pavlovsky, C. and Pagnano, K. and Moiraghi, B. and Varela, AI. and Bianchini, M. and Mayer, Jiří and Žáčková, Daniela and Kvetková, Anežka and Jurček, Tomáš and Ježíšková, Ivana and Lopes, ABP. and Duarte, G. and Souza, CA. and Medeiros, J. and Kim, TS. and Yoo, YS. and Kim, KH. and Lee, HW. and Chang, MH. and Yi, SY. and Abelson, S. and Kim, D.}, booktitle = {64th ASH Annual Meeting and Exposition, USA, New Orleans, prosinec 2022 in Blood}, title = {Somatic mutations are frequently detected in CML patients before treatment-free remission (TFR) attempt with tyrosine kinase inhibitor (TKI) discontinuation but with uncertain predictive valu efor Tfr failure}, year = {2022} }
TY - CONF ID - 2241222 AU - Perusini, MA. - Pagnano, K. - Pavlovsky, C. - Pagnano, K. - Moiraghi, B. - Varela, AI. - Bianchini, M. - Mayer, Jiří - Žáčková, Daniela - Kvetková, Anežka - Jurček, Tomáš - Ježíšková, Ivana - Lopes, ABP. - Duarte, G. - Souza, CA. - Medeiros, J. - Kim, TS. - Yoo, YS. - Kim, KH. - Lee, HW. - Chang, MH. - Yi, SY. - Abelson, S. - Kim, D. PY - 2022 TI - Somatic mutations are frequently detected in CML patients before treatment-free remission (TFR) attempt with tyrosine kinase inhibitor (TKI) discontinuation but with uncertain predictive valu efor Tfr failure ER -
PERUSINI, MA., K. PAGNANO, C. PAVLOVSKY, K. PAGNANO, B. MOIRAGHI, AI. VARELA, M. BIANCHINI, Jiří MAYER, Daniela ŽÁČKOVÁ, Anežka KVETKOVÁ, Tomáš JURČEK, Ivana JEŽÍŠKOVÁ, ABP. LOPES, G. DUARTE, CA. SOUZA, J. MEDEIROS, TS. KIM, YS. YOO, KH. KIM, HW. LEE, MH. CHANG, SY. YI, S. ABELSON a D. KIM. Somatic mutations are frequently detected in CML patients before treatment-free remission (TFR) attempt with tyrosine kinase inhibitor (TKI) discontinuation but with uncertain predictive valu efor Tfr failure. In \textit{64th ASH Annual Meeting and Exposition, USA, New Orleans, prosinec 2022 in Blood}. 2022.